Cytokinetics (CYTK) Misses Q3 EPS by 13c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $78.78 --0%
Revenue Growth %: -75.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -75.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.36), $0.13 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $463 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- GXO opens distribution center in Italy for Action stores
- Seer and Korea University share early cancer screening proteomics data
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
